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Somatic hypermutation (SHM) of immunoglobulin genes is currently viewed as a two step process initiated by the deamination
of deoxycytidine (C) to deoxyuridine (U), catalysed by the activation induced deaminase (AID). Phase 1 mutations arise from
DNA replication across the uracil residue or the abasic site, generated by the uracil-DNA glycosylase, yielding transitions or
transversions at G:C pairs. Phase 2 mutations result from the recognition of the U:G mismatch by the Msh2/Msh6 complex
(MutS Homologue), followed by the excision of the mismatched nucleotide and the repair, by the low fidelity DNA polymerase
g, of the gap generated by the exonuclease I. These mutations are mainly focused at A:T pairs. Whereas in activated B cells
both G:C and A:T pairs are equally targeted, ectopic expression of AID was shown to trigger only G:C mutations on a stably
integrated reporter gene. Here we show that when using non-replicative episomal vectors containing a GFP gene, inactivated
by the introduction of stop codons at various positions, a high level of EGFP positive cells was obtained after transient
expression in Jurkat cells constitutively expressing AID. We show that mutations at G:C and A:T pairs are produced. EGFP
positive cells are obtained in the absence of vector replication demonstrating that the mutations are dependent only on the
mismatch repair (MMR) pathway. This implies that the generation of phase 1 mutations is not a prerequisite for the expression
of phase 2 mutations.
Citation: Jovanic T, Roche B, Attal-Bonnefoy G, Leclercq O, Rougeon F (2008) Ectopic Expression of AID in a Non-B Cell Line Triggers A:T and G:C Point
Mutations in Non-Replicating Episomal Vectors. PLoS ONE 3(1): e1480. doi:10.1371/journal.pone.0001480
INTRODUCTION
Affinity maturation of the humoral immune response arises from
the stepwise introduction of single nucleotide substitutions into the
variable regions of immunoglobulin genes during B cell prolifer-
ation in germinal centers. This process is known as somatic
hypermutation (SHM) and depends on the expression of AID, the
activation induced cytidine deaminase whose expression is
restricted to centroblast B cells [1,2].
Analysis of the altered mutation pattern in mice deficient in
MSH2, a mismatch repair (MMR) protein, led to the proposal that
SHM is a two step process. SHM is initiated by deamination of
deoxycytidine (C) to deoxyuridine (U) in single-stranded DNA,
produced during the transcription of the variable (V) gene. Phase 1
mutations are introduced during replication across the G:U
mismatch and result in G:C to A:T transitions. If the U base is
removed before replication by uracil-DNA glycosylase, the
replication of the abasic site, created by a translesion DNA
polymerase, gives rise to both transitions and transversions. Phase
2 mutations are mainly restricted to A:T pairs surrounding a U:G
mismatch and involve the mismatch repair machinery. The
recognition of the U:G mismatch by the Msh2/Msh6 complex
results in a mutagenic patch repair mechanism involving
exonuclease I and the low-fidelity DNA polymerase g (POLG)
[3–5]. In activated B cells, G:C and A:T pairs are equally targeted
at V genes. However, in B cell lines, as well in non-B cell lines in
which AID is ectopically expressed, mutations at G:C pairs are
mainly found [6–8]; why mutations at A:T pairs are almost always
absent remains unclear. In activated B cells, A:T mutations are
strictly dependent on the Msh2/Msh6 pathway and are presumed
to be introduced during patch repair by POLH, in the absence of
DNA replication [9,10]. The function of MMR is to ensure the
fidelity of DNA replication by removing mismatches produced
during DNA synthesis [11,12]. The absence of mutations at A:T
pairs in B or non-B cell lines expressing AID could be explained
either by the prevalence of phase 1 mutations at G:C pairs
preventing MMR from occurring or, alternatively, by recruiting a
high fidelity DNA polymerase during the patch repair.
In order to examine if AID is able to trigger mutations in the
absence of DNA replication in a non-B cell line, we developed a
highly sensitive assay based on the reversion of nonsense mutations
of the EGFP gene cloned in a non replicating vector. We show
that the appearance of EGFP positive cells in non-B cells is
dependent on the expression of AID and that, even in the absence
of vector replication, mutations are found both at A:T pairs and at
G:C pairs.
RESULTS
The system we developed to study AID-dependent mutation is a
simian virus 40 (SV40) -based vector containing a mutated EGFP
gene to score mutations (SHM vectors: Figure 1A and B). We
transfected the SHM vectors into cells that do not express the T
antigen to prevent the plasmids from replicating, which was
confirmed by a DpnI replication assay (data not shown). Because
an essential component for plasmid replication is missing, only
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The EGFP gene was mutated by introducing a premature stop
codon, TAG or TAA (Figure 1C). The mutated EGFP protein is
truncated and non-fluorescent. If the stop codon reverts
fluorescence is restored and the cells can be detected by flow
cytometry in the green fluorescence channel. The number of
vector molecules present in transfected cells can not be evaluated
precisely thus, it is not possible to estimate a mutation rate. The
mutation level is, therefore, a relative value and corresponds to the
percentage of fluorescent cells. This value depends on the
percentage of cells transfected with an SHM vector. Consequently,
the mutation level was expressed as the percentage of fluorescent
cells relative to the transfection efficiency. Transfection efficiency
was estimated using a plasmid containing a wild-type EGFP gene
and was typically around 30–50% in Jurkat cells, 15–35% in
Jurkat-AID cells.
SHM vectors were transfected into AID-expressing cell lines
and compared to a control cell line that does not express AID. The
cell lines used were a T lymphoma cell line, Jurkat, and its AID-
expressing counterpart, Jurkat-AID. The expression of AID was
tested by RT-PCR analyses of the Jurkat and Jurkat-AID cells
(Figure 2). The Jurkat-AID clone used in this study over-expresses
AID, as illustrated in Figure 2.
AID-dependent mutations are detected in SHM
vectors less than 20 hours after transfection
To determine whether AID-induced mutations can be detected
using SHM vectors, we first tested the pmutEGFP-TAG182 vector
(depicted in Figure 1) in Jurkat and Jurkat-AID cells. As shown in
Figure 3, the TAG-182 codon reverted significantly more
frequently (0.3% +/2 SD versus 8.1% +/2SD) in Jurkat-AID
cells compared to Jurkat cells that do not express AID. To verify
whether EGFP revertants are generated only by point mutations, a
vector containing a 4-nucleotide deletion at position 52, which
results in a stop codon, was transfected. The 4-nucleotide deletion
substrate did not give rise to a functional EGFP gene in any of the
cell lines transfected (data not shown). Thus, the mutations which
Figure 1. SHM vectors used to monitor SHM in AID-expressing cell lines (A) pmutEGFP vector: EGFP (enhanced green fluorescent protein), a
variant of the GFP gene, is placed under the control of the CMV promoter (human cytomegalovirus immediate-early promoter/enhancer); pUC–
prokaryotic origin of replication; AMP
R –ampicillin resistance gene; SV40 ori–eukaryotic origin of replication; Kan
R/Neo
R–kanamycin/neomycin
resistance gene (B) pEM7-EGFP vector: EGFP is placed under the control of both an eukaryotic (CMV) and prokaryoric (EM7) promoter; pUC–
prokaryotic origin of replication; SV40 ori–eukaryotic origin of replication; Kan
R/Neo
R–kanamycin/neomycin resistance gene (C) Sequence
contexts of premature stop codons in the EGFP gene. The upper row corresponds to the wild-type sequences and the lower row to the mutated
sequences. Three variants of the EGFP gene inactivated with a premature termination codon introduced by site-directed mutagenesis were used 1)
The G of the TAG termination codon at the position 182 is embedded within the RGYW hotspot motif and is thus a potential target of AID 2) The TAG
stop codon at position 52 lies within two RGYW motifs 3) TAA codon at position 52 is used to monitor A:T mutations only. RGYW motifs are shown in
bold letters. The mutated nucleotides are underlined.
doi:10.1371/journal.pone.0001480.g001
Figure 2. AID is transcribed in the Jurkat-AID and not in the control
Jurkat cell line. AID transcription was monitored with RT-PCR in a
control cell line, Jurkat, and in a Jurkat-AID cell line stably transfected
with AID. A Burkitt lymphoma cell line Ramos constitutively expressing
AID was used as a positive control for AID expression. G3PDH was used
as an internal control. The bands corresponding to AID (380 bp) and
G3PDH (1000 bp) are shown with black arrows.
doi:10.1371/journal.pone.0001480.g002
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stop codon. This event is AID dependent, as illustrated in Figure. 3.
In general, cells were analyzed by flow cytometry 20 hours after
transfection. The maximum number of EGFP positive cells is
observed between 12 and 24 hours. 24 hours after transfection
1.7% of Jurkat-AID cells reverted the TAG 182 codon.
Surprisingly, we found that mutations appear very rapidly after
transfection: we were able to observe EGFP positive cells within
3 hours of transfection (Figure 4). This suggests that mutations
occur immediately after the DNA enters the cell.
Together these data demonstrate that AID dependent muta-
tions can be detected with SHM vectors less than 24 hours after
transfection.
Ectopic expression of AID triggers both G:C and A:T
mutations
In order to characterize the molecular events responsible for the
introduction of point mutations in the absence of DNA replication,
we constructed two new vectors in addition to pmutEGFP-
TAG182 : pmutEGFP-TAG52 and pmutEGFP-TAA52 which
contain different stop codons at position 52 of the EGFP gene.
These SHM vectors were transfected into Jurkat and Jurkat-AID
cells and analyzed by flow cytometry 20 hours after transfection,
as previously described. Figure 5 shows that all the three vectors,
bearing different stop codons, were mutated more efficiently in the
Jurkat-AID than in the Jurkat cell line. The TAG-52 mutation
reverted in both transfected cell lines, at a higher level compared
to the other mutations. It reverted at a sevenfold higher level in
Jurkat-AID cells compared to Jurkat cells.
In order to identify which reverse mutation confers the
fluorescent phenotype, we constructed a second series of vectors,
pEM7 SHM vectors, with the EGFP gene under the control of
both a prokaryotic (EM7) and a eukaryotic (CMV) promoter.
These vectors allowed us to extract plasmid DNA after
transfection and transform bacteria to analyze individual fluores-
Figure 3. The pmutEGFP-TAG182 SHM vector was tested in Jurkat
and Jurkat-AID cell lines. Twenty hours after transfection cells were
analyzed on a FACS Scan. Cells that have reverted the stop codon of
one or more copies of the vector appear fluorescent. The percentage of
fluorescent cells relative to transfection efficiency was monitored using
a wild-type EGFP vector. The experiment was repeated 4 times. An
average of 8.1% of transfected Jurkat-AID cells reverted the stop codon,
compared to 0.29% of non-transfected Jurkat cells.
doi:10.1371/journal.pone.0001480.g003
Figure 4. Mutations can be detected very rapidly using SHM vectors.
Jurkat and Jurkat-AID cells were transfected with the pmutEGFP-
TAG182 SHM vector. Fluorescent cells were detected 3 and 24 hours
after transfection. Three hours after transfection, 0.23% of fluorescent
Jurkat-AID cells are observed and 1.68% had reverted 24 hours after
transfection.
doi:10.1371/journal.pone.0001480.g004
Figure 5. Both G:C and A:T mutations are detected in Jurkat-AID cells.
G:C and A:T focused mutations were monitored using pmutEGFP-
TAG182, pmutEGFP-TAG52 and pmutEGFP-TAA52 SHM vectors. The
experiment was repeated four times for TAG-182 and TAG-52 codons
and three times for the TAA-52 codon. The average value of these
independent experiments is represented. The percentage of fluorescent
cells was calculated relative to transfection efficiency which was
monitored using a wild-type EGFP vector. Twenty hours after
transfection, 8.1% of Jurkat-AID cells reverted the TAG-182 codon,
27.08% the TAG-52 codon and 13.22% the TAA codon. Less than 1% of
Jurkat cells reverted TAG-182 and TAA-52 codons and TAG-52 reverted
in 3.97% of the transfected cells.
doi:10.1371/journal.pone.0001480.g005
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into Jurkat and Jurkat-AID cells.
The vectors used were pEM7-EGFP-TAG182, pEM7-EGFP-
TAG52 and pEM7-EGFP-TAA52 (Figure 1B and C). The
reversion efficiency of EM7 SHM vectors (data not shown) is
similar to those of SHM vectors (Figure 5).
To identify the nucleotide within the stop codon that is mutated
in revertants of TAG-52 and TAG-182 SHM vectors, we first
sorted out fluorescent cells, then extracted plasmid DNA after
secondary cloning in E.coli. Sequencing data demonstrate that the
TAG-52 codon is mutated at the first T:A base pair (Table 1),
TAG-182 is mutated at the G:C base pair in Jurkat-AID cells
(Table 1). Interestingly, in the case of TAA-52, one revertant
sequence bears a point mutation to TAC, thus mutated at the
third A:T base pair, instead of the expected reversion to AAA or
wild-type AAG (Table 1). This encodes a tyrosine instead of a
lysine and despite these aminoacid differences, this restored the
fluorescent phenotype. No mutations were detected outside the
stop codon in any of the 24 revertant sequences analyzed. In order
to examine the overall distribution of mutations in the EGFP gene
we sequenced the gene from 178 non-fluorescent colonies, 106
from Jurkat-AID cells and 72 from Jurkat cells. This analysis
uncovered only two point mutations that were observed on
plasmids from Jurkat-AID cells. The two mutations were the same:
a G to A transition positioned near the end of the EGFP gene and
seem to correspond to the same mutational event (data not shown).
DISCUSSION
In the present study we made use of non-replicating episomal
vectors to study AID induced mutagenesis in a non-B cell context.
Our system is based on the reversion of a nonsense mutation in an
EGFP gene, cloned downstream of the CMV promoter/enhancer.
The data demonstrate that transiently transfected DNA can be
mutated in a AID dependent manner in non-B cells. Both G:C
and A:T mutations were detected, suggesting that the lesion
introduced by AID is sufficient for triggering both types of
mutations. The high sensitivity of our transient assay is probably
due to the high plasmid copy number introduced in each cell (10
5-
10
6 per cell) and to the fact that the reversion of only one stop
codon per cell is sufficient to be detected on a FACS analyzer.
In general, phase 1 mutations, located at the level of the U:G
mispairs, are only found after the replication fork has passed the
abasic site produced by uracil-DNA glycosylase and a dNTP has
been inserted opposite the abasic site. The fact that the reporter
gene can not replicate demonstrates that, not only G:C, but also
A:T mutations are not typical phase 1 mutations.
How can we explain the mutability of the reporter gene in the
absence of DNA replication in Jurkat-AID cells? Numerous studies
have shown that the rate of mutation of V regions is proportional to
the rate of transcription. The biochemical demonstration that AID
deaminates C in single stranded (ss) DNA led to the proposal that
transcription triggers separation of the DNA strands, each ss DNA is
then exposed to the action of AID [6,14–17]. The EGFP reporter
gene is under the control of a strong promoter and this could explain
itshighmutability,caused bythe formationofssDNAcreated bythe
supercoiling of the DNA. It is interesting to observe that all three
types of codons were reverted inthe Jurkat-AID cellline and that the
TAG-52 codon also reverted at a significant level in Jurkat cells
without AID. The high mutability of the TAG-52 codon can be
explained by the influence of secondary structures. Wright and
coworkers showed that the position of the nucleotide within the stem
loop structure determines the mutability of the nucleotide in
prokaryotes [18] and in eukaryotes [19,20]. The most hypermutable
basesare located immediatelynext to stemsinstableDNA stem-loop
structures (SLS). In light of this, we can assume that the background
mutation for the TAG-52 codon, which lies within two adjacent
hotspot motifs, is considerably higher compared to the other codons,
due to a secondary structure effect (SLS effect). This phenomenon is
amplified in AID expressing cells.
How can the formation of a U:G mismatch by AID trigger the
reversion of the stop codons? Theoretically the elimination of a
mismatch in non-dividing cells by MMR can operate without
distinguishing between the two DNA strands [21]. In the case of a
U:G mismatch this results, with equal probability, either in a G:C
R A:T transition or in the maintenance of the sequence. Clearly
none of the reversions of the three stop codons in the EGFP gene
correspond to a G:C R A:T transition. We therefore postulate
that the reversion of the stop codon is introduced during MMR.
MMR involves the recognition of the U:G mismatch by the
Msh2/Msh6 heterodimer, endonucleotide cleavage of one of the
DNA strands and the creation of a gap by exonuclease I. While
gap repair is usually error-free due to the activity of high fidelity
DNA polymerase d & e [12,22], during phase 2 of SHM, the gap
could be repaired by error-prone DNA polymerases that insert
mispaired nucleotides at A:T pairs [10,23]. A key question is why
the mechanism that normally insures the fidelity of DNA repair in
non-B cells seems ineffective in Jurkat-AID cells? DNA mismatch
repair is normally used to correct mispairing occurring during
DNA replication. Its efficiency is based on its ability to distinguish
between parental and neosynthetized DNA strands. In the absence
of DNA replication a mismatch will be repaired with equal
probability to fix the mutation or to restore the wild type sequence.
If theorically mutagenic mismatch repair in the absence of DNA
replication does not require a specialized DNA polymerase, the
high rate of mutation observed during SHM is achieved by the
recruitment of specialized error-prone DNA polymerase [23,24].
These results strongly support the view that, even in non
dividing cells, mismatch repair can trigger mutations at distance
from the initial mismatch. In addition, phase 2 mutations can be
expressed independently of phase 1 mutations, before the passage
of the replication fork.
MATERIALS AND METHODS
Plasmid constructions
pmutEGFP-TAG182, pmutEGFP-TAG52, pmutEGFP-TAA52
were obtained as follows. First, an AseI MluI fragment from the
pEGFP-C1 plasmid (Clontech) was inserted into an XhoI site (after
Klenow fragment (KF) treatment) of the pBluescript sk+ plasmid
(Stratagene) to create psK+EGFP. A Bsu36I fragment from the
pEGFPC1 plasmid was cloned into an EcoRV site of the
pSK+EGFP vector to obtain the pEGFPcontr vector. This vector
was mutated by the site-directed mutagenesis kit (Stratagene) using
the following primers: TAG-182 mutation, pTAG182a (gctcgccgac-
cactAGCAgcagaacaccccc) and pTAG182b (gggggtgttctgcTGCT-
Table 1. Reversion status of plasmids rescued from
fluorescent colonies
......................................................................
Vector type Cell type Reversion sequence G:C or A:T mutation
TAG-52 jurkat ...GGC AAG CTG... A:T
TAG-52 jurkat-AID ...GGC AAG CTG... A:T
TAG-182 jurkat-AID ...CAC TAC CAG... G:C
TAA-52 jurkat-AID ...GGC TAC CTG... A:T
doi:10.1371/journal.pone.0001480.t001
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Tagctgcccgtgccctg) and pTAG52b (cagggcacgggcagctAGCCggtg-
gtgcagatg); TAA-52 mutation, pTAA52a (catctgcaccaccGGCTaAc-
tgcccgtgccctg) and pTAA52b (cagggcacgggcagTtAGCCggtggtgca-
gatg).
The second series of vectors enables the transcription of EGFP
in both eukaryotic and prokaryotic cells. pEM7-EGFP is based on
the pEGFP-C1 vector (Clontech). pEGFP-C1 was digested with
NheI and XhoI and recirculized to obtain the P1 vector. The EM7
promoter was obtained by annealing 2 oligos EM7EcoRI/AfeI 1
(aattcTGTTGACAATTAATCATCGGCATAGTATATCGGC-
ATAGTATAATACGAAGGTGAGGAACTAAAccatgagcgct)
and 2 (agcgctcatggTTTAGTTCCTCACCTTGTCGTATTA-
TACTATGCCGATATACTATGCCGATGATTAATTGTCA-
ACAg) (phosphorylated at the 59 end). The pEM7 plasmid was
obtained after introduction of the EM7 promoter into EcoRI and
SmaI digested P1. pEM7 was digested with AfeI and BamHI. The
EGFP insert with a 39 BamHI site was prepared by PCR of
pEGFPcontr, pmutEGFP-TAG182, pmutEGFP-TAG52 and
pmutEGFP-TAA52 using the following primers: 59GFP (aagggc-
gaggagctgttcaccG) and 39GFP (AGGGTAGGATCCcttgtac
agctcgtccat). A BamHI site was inserted into the 39 primer. The
PCR product was digested with BamHI and cloned into the pEM7
vector in order to obtain pEM7-EGFPcontr, pEM7-EGFP-
TAG182, pEM7-EGFPTAG52 and pEM7-EGFPTAA52 vectors.
pCDNA3.1AID was constructed as follows. AID cDNA was
obtained from a cDNA library of Ramos cells (produced using the
Creator SMART cDNA Library Construction Kit from Clontech)
and initially cloned into the pCDNA-LIB plasmid (Clontech). AID
cDNA was amplified by PCR and then transferred into the pET28
plasmid (Novagen) using NheI and XhoI sites, pCDNA3.1AID
was obtained by cloning AID in the NheI and XhoI sites of
pCDNA3.1HisA (Invitrogen).
Cell lines
The Jurkat cell line is a T lymphoma cell line that does not express
AID. Jurkat-AID cell lines were obtained by transfection of the
Jurkat cell line with pCDNA3.1AID. 10 mg of plasmid was used
for transfection of 1610
7 cells by electroporation. 48 hours after
transfection G418 (neomycin) was added for selection at a final
concentration of 2 mg/ml and cells were distributed in three 96
well plates at a concentration of 3 cells/well. After approximately
three weeks of selection, clones were obtained, amplified and
tested for AID expression by RT-PCR (see below).
Cell culture and transfection
Jurkat and Jurkat-AID cell lines were cultured in RPMI glutamax,
with 10% FCS, 100 units/ml penicillin and 100 mg/ml strepto-
mycin, and 2 mg/ml G418 for the Jurkat-AID cell line at 37uC,
5% CO2. In transfection experiments 25 mg of SHM vector DNA
were introduced by electroporation into 1610
7 Jurkat and Jurkat-
AID cells in 0.4 cm cuvettes using a Biorad Gene pulse electro-
porator. The conditions used were: 260 V, 975 mF, R=‘. After
transfection, cells were resuspended in 10 ml of fresh medium and
cultured at 37uC, 5% CO2 for 20 h (except when otherwise
indicated). As a transfection control, 25 mg of plasmid expressing
wild-type, fluorescent EGFP were transfected.
Flow cytometry
Twenty hours (except when otherwise indicated) after transfection,
5 ml of transfected cells were centrifuged and resuspended with
PBS, 0.5% FCS, 2 mM EDTA, 0.5 mg/ml propidium iodide
(dead cell marker) and analyzed by flow cytometry on a FACS
Scan (BD Biosciences). The acquisition was carried out on 500 000
cells. Analysis of the acquired data was performed with the «Cell
Quest» software (BD Sciences, Mountain View, CA). For plasmid
sequencing, fluorescent cells were sorted on a Moflo cell sorter
(DakoCytomation) before extraction in order to concentrate
fluorescent colonies (see below).
Extraction of plasmid DNA from mammalian cells
The NucleoSpin Plasmid (Macherey Nagel) kit for extraction of
plasmid DNA from bacteria was adapted to extract plasmid from
mammalian cells. Twenty hours after transfection 5 ml of
transfected cells were washed with PBS, centrifuged and subjected
to extraction. After resuspension and lysis (according to manufac-
turer’s instructions), the material was treated with 800 mg/ml
proteinase K for 1 h to 2 h at 55uC. Proteinase K digestion was
followed by neutralization, column fixation, washing and elution
(according to manufacturer’s instructions). In the DNA replication
assay plasmid DNA was digested with DpnI 2 h at 37uC.
Transformation in E.coli and sequencing
2 ml of extracted DNA was transformed in TOP10 bacteria
(Invitrogen) and resuspended in 900 ml of SOC medium. The total
suspension was plated on LB kanamycin (50 mg/ml) plates, 100–
200 ml of bacteria suspension per plate. Plates were analyzed on a
Lighttools Illuminatool Tunable Lighting System. Fluorescent
colonies were grown in 4 ml LB kanamycin medium overnight.
Plasmid DNA was extracted using NucleoSpin Plasmid (Macherey
Nagel) kit according to manufacturer’s instructions and sent for
sequencing using a CMV primer (gtacggtgggaggtctatataagcag).
AID RT-PCR
Total RNA was extracted from Jurkat, Jurkat-AID and Ramos
cells using the Trizol reagent (Invitrogen) according to manufac-
turer’s instructions. Two mg of RNA was denatured 5 minutes at
65uC with 0.5 mg of oligo dT and chilled on ice. Reverse tran-
scription was performed in a 50 ml reaction for 90 minutes at 37uC
with 1xMMLV buffer, 0.5 mM dNTPs, 10 mM dithiotreitol,
200 U of MMLV (all from Invitrogen) and 400 U/ml RNAsin
(Promega). The MMLV was inactivated at 70uC for 15 min. 2 ml
of the cDNA was used for each PCR reaction: AID and G3PDH.
PCR was conducted using Taq polymerase (Qiagen), according to
manufacturer’s instructions, in a 50 ml reaction using 0.4 mMo f
the following primers: AID1 (TAGACCCTGGCCGCTGCTA-
CC) and AID2 (CAAAAGGATGCGCCGAAGCTGTCTGG-
AG) for AID amplification, G3PDH1 (TGAAGGTCGGAGT-
CAACGGATTTGGT) and G3PDH2 (CATGTGGCCATGAG-
GTCCACCAC) for G3PDH amplification. The cycling used for
both PCRs is 94uC/2 min, 15 cycles of 94uC, 15s; 65uC, 30s;
72uC, 45s, 30 cycles of 94uC, 15s; 65uC, 30s; 72uC, 45s+5s every
cycle and 7 minutes at 72uC.
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